Today: 9 June 2026
Browse Category

NASDAQ:PAYX 10 July 2025 - 11 February 2026

Why Barrett Business Services (BBSI) stock is sliding today as HR outsourcing names sink

Why Barrett Business Services (BBSI) stock is sliding today as HR outsourcing names sink

Barrett Business Services shares fell 7.6% to $32.77 Wednesday afternoon, hitting a session low amid a sector-wide selloff in HR outsourcing stocks. Insperity dropped 12.1% after posting a quarterly net loss and higher benefits costs. No company-specific news drove BBSI’s decline. Investors cited mixed U.S. jobs data and concerns over benefit expenses ahead of Friday’s inflation report.
11 February 2026
····
Boss’s Day Bombshell: 75% of Employees Actually LIKE Their Boss – New Survey Shatters Stereotypes

Boss’s Day Bombshell: 75% of Employees Actually LIKE Their Boss – New Survey Shatters Stereotypes

A GroupTogether survey of 1,260 U.S. workers found 75.9% like their boss, citing team culture and kindness as top reasons. Gallup data shows manager quality drives about 70% of team engagement. U.S. employee engagement is at a 10-year low, with younger workers most affected. HR tech and AI tools are expanding rapidly, with Workday’s AI “Recruiting Agent” reducing resume screening time by 57%.
14 October 2025
··
Global HCM Software Market Update (June–July 2025) – Key Trends, News & Forecasts

Global HCM Software Market Update (June–July 2025) – Key Trends, News & Forecasts

The global HR/HCM and payroll software market is projected to reach $57.8 billion by 2029 and $91.7 billion by 2034, growing about 10% annually. North America holds 36% of revenue, while Asia-Pacific leads in growth at 12% CAGR. The top 10 vendors account for just 10% of 2023 revenue. A surge in AI product launches in mid-2025 prompted a 45% annual growth forecast for AI-powered HR agents.
10 July 2025
········

Stock Market Today

  • Designer Brands (DBI) Beats Q1 Earnings and Revenue Estimates
    June 9, 2026, 10:04 AM EDT. Designer Brands (DBI) reported Q1 earnings of $0.07 per share, surpassing the Zacks estimate of $0.02 and reversing a year-ago loss of $0.26. Revenue hit $696.35 million, just above the $696 million consensus. The company delivered a 250% earnings surprise and has beaten EPS estimates in four consecutive quarters. Shares rose about 19.5% year-to-date, outpacing the S&P 500's 8.2% gain. Despite strong results, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. The Retail - Apparel and Shoes sector ranks among the top three industries. Future stock performance will depend on management's outlook and upcoming earnings estimate revisions, with current consensus estimates at $0.30 EPS on $744 million revenue next quarter and $0.35 EPS on $2.91 billion revenue for the fiscal year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop